Aytu Biopharma, Inc (AYTU) Stock Price & Analysis
Aytu Biopharma, Inc (AYTU) rose 0.22% to USD 2.3 as of June 10, 2026 at 03:13 UTC, according to Nexqual real-time market data.
AYTU last closed at USD 2.3; the session ranged USD 2.24–2.35 on volume of 35,470 shares. Market capitalization is $24.69M, with a 52-week range of USD 1.65–3.07 (NCM). Source: Nexqual, June 10, 2026 at 03:13 UTC.
Key Statistics (as of June 10, 2026 at 03:13 UTC)
| Price | USD 2.3 |
|---|---|
| Change | ▲ 0.22% (up) |
| Previous Close | USD 2.3 |
| Open | USD 2.25 |
| Day Range | USD 2.24 – 2.35 |
| 52-Week Range | USD 1.65 – 3.07 |
| Volume | 35,470 shares |
| Market Cap | $24.69M |
| Exchange | NCM |
Technical Analysis (AYTU)
Nexqual's technical model rates AYTU "SELL" based on 2 bullish and 4 bearish signals across 124 daily candles, as of June 10, 2026 at 03:13 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 51.4 (neutral) |
| vs SMA50 | Below (USD 2.42) |
| MACD | -0.05 (negative) |
Analyst Ratings (AYTU)
Wall Street analysts rate AYTU "None" based on 3 analysts, with a mean price target of USD 9.33 (range USD 7–14), per Nexqual as of June 10, 2026 at 03:13 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 9.33 |
| High Target | USD 14 |
| Low Target | USD 7 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (AYTU)
| EPS Estimate | USD -0.29 |
|---|---|
| Revenue Estimate | $12.41M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.41 vs est -0.43 ▲ beat |
| 2025-12-31 | USD -0.23 vs est -0.5 ▲ beat |
| 2025-09-30 | USD -0.09 vs est -0.2 ▲ beat |
| 2025-06-30 | USD -0.08 vs est -0.06 ▼ miss |
Source: Nexqual, June 10, 2026 at 03:13 UTC.
Financials & Fundamentals (AYTU)
| Total Revenue | $56.60M |
|---|---|
| Revenue Growth (YoY) | -32.70% |
| Gross Margin | +64.78% |
| Operating Margin | -32.74% |
| Profit Margin | -60.17% |
| ROE | -97.42% |
| Debt / Equity | 62.08 |
| Current Ratio | 1.12 |
| Total Cash | $26.71M |
| Total Debt | $21.82M |
| Free Cash Flow | $-1.07M |
Source: Nexqual, June 10, 2026 at 03:13 UTC.
Financial Health Score (AYTU)
Nexqual rates Aytu Biopharma, Inc's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:13 UTC.
| Growth | Critical — Revenue -18% YoY (annual), sharp decline |
|---|---|
| Profitability | Solid — Gross margin 65%, operating -33% |
| Balance Sheet | Solid — $27M cash vs $22M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$1M, burning cash |
| Efficiency | Critical — ROE -97%, ROA -3.7% |
Ownership (AYTU)
| Insider Ownership | +8.98% |
|---|---|
| Institutional Ownership | +36.58% |
| Shares Outstanding | 10.73M |
| Float | 7.61M |
| Short % of Float | +4.43% |
Source: Nexqual, June 10, 2026 at 03:13 UTC.
Leadership (AYTU)
Aytu Biopharma, Inc is led by Joshua R. Disbrow (age 50), CEO & Director, per Nexqual as of June 10, 2026 at 03:13 UTC.
| CEO & Director | Joshua R. Disbrow (age 50) |
|---|---|
| CFO, Corporate Secretary & Treasurer | Ryan J. Selhorn (age 43) |
| Vice President of Operations | Margaret Cabano |
| Senior Vice President of Scientific Affairs | Gerwin Westfield |
Major Backers & Investors (AYTU)
Notable institutional backers of Aytu Biopharma, Inc include Nantahala Capital Management, LLC, Stonepine Capital Management, LLC, AWM Investment Company, Inc., according to Nexqual as of June 10, 2026 at 03:13 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Nantahala Capital Management, LLC | 10.13% |
| Stonepine Capital Management, LLC | 7.38% |
| AWM Investment Company, Inc. | 5.77% |
| Diadema Partners LP | 3.29% |
| Crown Advisors Management, Inc. | 1.35% |
| Two Sigma Investments, LP | 1.14% |
| Persistent Asset Partners Ltd | 0.87% |
| Renaissance Technologies | 0.87% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 4.76% |
| Geode Capital | 0.86% |
Source: Nexqual, June 10, 2026 at 03:13 UTC.
From Aytu Biopharma, Inc's Latest SEC 10-K Filing (filed 2025-09-23)
Key Strengths & Strategy (as disclosed to the SEC)
- Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally.
- The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD.
- It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CODX | Co-Diagnostics, Inc. | USD 4.5 | ▼ 20.07% |
| AIM | AIM ImmunoTech Inc. | USD 0.4 | ▼ 22.5% |
| IBIO | iBio, Inc. | USD 1.7 | ▼ 6.59% |
| CFOR | OpGen, Inc. | USD 2 | ▲ 300% |
| COCP | Cocrystal Pharma, Inc. | USD 1.02 | ▲ 6.25% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:13 UTC. This page is informational and not investment advice.